Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GW Pharmaceuticals PLC

www.gwpharm.com

Latest From GW Pharmaceuticals PLC

Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen

The latest drug development news and highlights from our US FDA Performance Tracker.

Performance Tracker Approvals

Zynerba’s Cannabidiol Failure in Focal Seizures Not So Clear-Cut

Zynerba’s gel formulation of cannabidiol has disappointed in top-line data from a Phase II study in epilepsy patients with focal seizures, but some signals of efficacy in a companion study, and expected data from studies in two other indications, might influence future development plans.

Clinical Trials Research & Development

Pipeline Watch: Top-Line Ozanimod, Romosozumab, Cariprazine Phase III Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

GW's Epidolex Epilepsy Data Paves Way For Cannabinoids

Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • GW Pharmaceuticals PLC
  • Senior Management
  • Justin Gover, CEO
    Scott Giacobello, CFO
    Stephen Wright, MD, Dir., R&D
    Chris Tovey, COO
  • Contact Info
  • GW Pharmaceuticals PLC
    Phone: (44) 1223 266800
    Sovereign House
    Vision Park
    Histon, Cambridge, CB24 9BZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register